Case-by-case combination of the prostate imaging reporting and data system version 2.1 with the Likert score to reduce the false-positives of prostate MRI: a proof-of-concept study.

Objectives: To retrospectively investigate whether a case-by-case combination of the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS) with the Likert score improves the diagnostic performance of mpMRI for clinically significant prostate cancer (csPCa), especially by reducing false-po...

Descripción completa

Detalles Bibliográficos
Publicado en:Abdominal Radiology Vol. 49; no. 12; pp. 4273 - 4286
Autores principales: Girometti, Rossano, Peruzzi, Valeria, Polizzi, Paolo, De Martino, Maria, Cereser, Lorenzo, Casarotto, Letizia, Pizzolitto, Stefano, Isola, Miriam, Crestani, Alessandro, Giannarini, Gianluca, Zuiani, Chiara
Formato: Journal Article
Publicado: Springer Nature Dec2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=180588296&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 180588296
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        2366004X
        JT14
      jtl: Abdominal Radiology
      issn: 2366004X
      maglogo: N
    pubinfo:
      dt: Dec2024
      vid: 49
      iid: 12
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        180588296
        178712203
        10.1007/s00261-024-04506-2
        180588296
      ppf: 4273
      ppct: 13
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Case-by-case combination of the prostate imaging reporting and data system version 2.1 with the Likert score to reduce the false-positives of prostate MRI: a proof-of-concept study.
      aug:
        au:
          Girometti, Rossano
          Peruzzi, Valeria
          Polizzi, Paolo
          De Martino, Maria
          Cereser, Lorenzo
          Casarotto, Letizia
          Pizzolitto, Stefano
          Isola, Miriam
          Crestani, Alessandro
          Giannarini, Gianluca
          Zuiani, Chiara
        affil: https://ror.org/05ht0mh31 Institute of Radiology, Department of Medicine (DMED), University of Udine, University Hospital S. Maria della Misericordia – Azienda Sanitaria-Universitaria Friuli Centrale (ASU FC), p.le S. Maria della Misericordia, 15 – 33100, Udine, Italy
      sug:
      ab: Objectives: To retrospectively investigate whether a case-by-case combination of the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS) with the Likert score improves the diagnostic performance of mpMRI for clinically significant prostate cancer (csPCa), especially by reducing false-positives. Methods: One hundred men received mpMRI between January 2020 and April 2021, followed by prostate biopsy. Reader 1 (R1) and reader 2 (R2) (experience of > 3000 and < 200 mpMRI readings) independently reviewed mpMRIs with the PI-RADS version 2.1. After unveiling clinical information, they were free to add (or not) a Likert score to upgrade or downgrade or reinforce the level of suspicion of the PI-RADS category attributed to the index lesion or, rather, identify a new index lesion. We calculated sensitivity, specificity, and predictive values of R1/R2 in detecting csPCa when biopsying PI-RADS ≥ 3 index-lesions (strategy 1) versus PI-RADS ≥ 3 or Likert ≥ 3 index-lesions (strategy 2), with decision curve analysis to assess the net benefit. In strategy 2, the Likert score was considered dominant in determining biopsy decisions. Results: csPCa prevalence was 38%. R1/R2 used combined PI-RADS and Likert categorization in 28%/18% of examinations relying mainly on clinical features such as prostate specific antigen level and digital rectal examination than imaging findings. The specificity/positive predictive values were 66.1/63.1% for R1 (95%CI 52.9–77.6/54.5–70.9) and 50.0/51.6% (95%CI 37.0-63.0/35.5-72.4%) for R2 in the case of PI-RADS-based readings, and 74.2/69.2% for R1 (95%CI 61.5–84.5/59.4–77.5%) and 56.6/54.2% (95%CI 43.3-69.0/37.1-76.6%) for R2 in the case of combined PI-RADS/Likert readings. Sensitivity/negative predictive values were unaffected. Strategy 2 achieved greater net benefit as a trigger of biopsy for R1 only. Conclusion: Case-by-case combination of the PI-RADS version 2.1 with Likert score translated into a mild but measurable impact in reducing the false-positives of PI-RADS categorization, though greater net benefit in reducing unnecessary biopsies was found in the experienced reader only.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N